Pfizer Enters into Agreement with 3SBio for Innovative Cancer Treatment
Friday, July 25, 2025
Pfizer has completed a global licensing agreement with 3SBio, excluding China, to develop, manufacture, and commercialise SSGJ-707 – a bispecific antibody targeting PD-1 and VEGF.
The therapy was developed using 3SBio’s proprietary CLF2 platform and adds to Pfizer’s expanding oncology portfolio, particularly in the field of immuno-oncology.
The agreement strengthens Pfizer’s position in cancer research, enabling it to explore new combination treatments across several key cancer types. SSGJ-707 is currently being studied in China in clinical trials for conditions including non-small cell lung cancer (NSCLC), metastatic colorectal cancer, and gynecological tumours. Interim Phase 2 results for advanced NSCLC have shown encouraging outcomes and were presented at the recent ASCO Annual Meeting.
Pfizer plans to produce the drug substance for SSGJ-707 at its facility in Sanford, North Carolina, and the drug product in McPherson, Kansas.
As part of the agreement, 3SBio will receive a payment of $1.25 billion. Pfizer will also invest $100 million in 3SBio through an equity transaction. The deal includes an option for Pfizer to obtain exclusive rights for SSGJ-707 in China, which could result in additional payments of up to $150 million if the option is exercised.
The development plan includes global trial sites, with an initial focus on launching Phase 3 studies for NSCLC and other solid tumours in the United States.
Source: pfizer.com
